Association between daidzein intake and metabolic associated fatty liver disease: A cross-sectional study from NHANES 2017–2018
BackgroundMetabolic associated fatty liver disease (MAFLD) has become the most common liver disease globally, yet no new drugs have been approved for clinical treatment. Therefore, we investigated the relationship between dietary intake of soy-derived daidzein and MAFLD, to find potentially effectiv...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-02-01
|
| Series: | Frontiers in Nutrition |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnut.2023.1113789/full |
| _version_ | 1811165361840586752 |
|---|---|
| author | Zheng Yang Daoqing Gong Xinxiang He Fei Huang Yi Sun Qinming Hu |
| author_facet | Zheng Yang Daoqing Gong Xinxiang He Fei Huang Yi Sun Qinming Hu |
| author_sort | Zheng Yang |
| collection | DOAJ |
| description | BackgroundMetabolic associated fatty liver disease (MAFLD) has become the most common liver disease globally, yet no new drugs have been approved for clinical treatment. Therefore, we investigated the relationship between dietary intake of soy-derived daidzein and MAFLD, to find potentially effective treatments.MethodsWe conducted a cross-sectional study using data from 1,476 participants in National Health and Nutrition Examination Survey (NHANES) from 2017 to 2018 and their associated daidzein intake from the flavonoid database in the USDA Food and Nutrient Database for Dietary Studies (FNDDS). We investigated the relationship between MAFLD status, controlled attenuation parameter (CAP), AST/Platelet Ratio Index (APRI), Fibrosis-4 Index (FIB-4), liver stiffness measurement (LSM), nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS), hepatic steatosis index (HSI), fatty liver index (FLI), and daidzein intake by adjusting for confounding variables using binary logistic regression models and linear regression models.ResultsIn the multivariable-adjusted model II, there was a negative association between daidzein intake and the incidence of MAFLD (OR for Q4 versus Q1 was 0.65, 95% confidence interval [CI] = 0.46–0.91, p = 0.0114, p for trend was 0.0190). CAP was also negatively associated with daidzein intake, β = −0.37, 95% CI: −0.63 to −0.12, p = 0.0046 in model II after adjusting for age, sex, race, marital status, education level, family income-to-poverty ratio (PIR), smoking, and alcohol consumption. Stratified by quartiles of daidzein intake, trend analysis of the relationship between daidzein intake and CAP remained significant (p for trend = 0.0054). In addition, we also found that HSI, FLI, and NFS were negatively correlated with daidzein intake. LSM was negatively related to daidzein intake but had no statistical significance. The correlation between APRI, FIB-4, and daidzein intake was not strong (although p < 0.05, β values were all 0).ConclusionWe found that MAFLD prevalence, CAP, HSI, and FLI, all decreased with increased daidzein intake, suggesting that daidzein intake may improve hepatic steatosis. Therefore, dietary patterns of soy food or supplement consumption may be a valuable strategy to reduce the disease burden and the prevalence of MAFLD. |
| first_indexed | 2024-04-10T15:37:06Z |
| format | Article |
| id | doaj.art-d49e8874779d4131aed38838b3213d36 |
| institution | Directory Open Access Journal |
| issn | 2296-861X |
| language | English |
| last_indexed | 2024-04-10T15:37:06Z |
| publishDate | 2023-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Nutrition |
| spelling | doaj.art-d49e8874779d4131aed38838b3213d362023-02-13T04:59:49ZengFrontiers Media S.A.Frontiers in Nutrition2296-861X2023-02-011010.3389/fnut.2023.11137891113789Association between daidzein intake and metabolic associated fatty liver disease: A cross-sectional study from NHANES 2017–2018Zheng Yang0Daoqing Gong1Xinxiang He2Fei Huang3Yi Sun4Qinming Hu5Department of Infectious Disease, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, ChinaTeaching Office, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, ChinaDepartment of Infectious Disease, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, ChinaDepartment of Infectious Disease, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, ChinaDepartment of Dermatology, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, ChinaDepartment of Infectious Disease, Jingzhou Hospital Affiliated to Yangtze University, Jingzhou, ChinaBackgroundMetabolic associated fatty liver disease (MAFLD) has become the most common liver disease globally, yet no new drugs have been approved for clinical treatment. Therefore, we investigated the relationship between dietary intake of soy-derived daidzein and MAFLD, to find potentially effective treatments.MethodsWe conducted a cross-sectional study using data from 1,476 participants in National Health and Nutrition Examination Survey (NHANES) from 2017 to 2018 and their associated daidzein intake from the flavonoid database in the USDA Food and Nutrient Database for Dietary Studies (FNDDS). We investigated the relationship between MAFLD status, controlled attenuation parameter (CAP), AST/Platelet Ratio Index (APRI), Fibrosis-4 Index (FIB-4), liver stiffness measurement (LSM), nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS), hepatic steatosis index (HSI), fatty liver index (FLI), and daidzein intake by adjusting for confounding variables using binary logistic regression models and linear regression models.ResultsIn the multivariable-adjusted model II, there was a negative association between daidzein intake and the incidence of MAFLD (OR for Q4 versus Q1 was 0.65, 95% confidence interval [CI] = 0.46–0.91, p = 0.0114, p for trend was 0.0190). CAP was also negatively associated with daidzein intake, β = −0.37, 95% CI: −0.63 to −0.12, p = 0.0046 in model II after adjusting for age, sex, race, marital status, education level, family income-to-poverty ratio (PIR), smoking, and alcohol consumption. Stratified by quartiles of daidzein intake, trend analysis of the relationship between daidzein intake and CAP remained significant (p for trend = 0.0054). In addition, we also found that HSI, FLI, and NFS were negatively correlated with daidzein intake. LSM was negatively related to daidzein intake but had no statistical significance. The correlation between APRI, FIB-4, and daidzein intake was not strong (although p < 0.05, β values were all 0).ConclusionWe found that MAFLD prevalence, CAP, HSI, and FLI, all decreased with increased daidzein intake, suggesting that daidzein intake may improve hepatic steatosis. Therefore, dietary patterns of soy food or supplement consumption may be a valuable strategy to reduce the disease burden and the prevalence of MAFLD.https://www.frontiersin.org/articles/10.3389/fnut.2023.1113789/fulldaidzeinMAFLDNHANEShepatic steatosishepatic fibrosis |
| spellingShingle | Zheng Yang Daoqing Gong Xinxiang He Fei Huang Yi Sun Qinming Hu Association between daidzein intake and metabolic associated fatty liver disease: A cross-sectional study from NHANES 2017–2018 Frontiers in Nutrition daidzein MAFLD NHANES hepatic steatosis hepatic fibrosis |
| title | Association between daidzein intake and metabolic associated fatty liver disease: A cross-sectional study from NHANES 2017–2018 |
| title_full | Association between daidzein intake and metabolic associated fatty liver disease: A cross-sectional study from NHANES 2017–2018 |
| title_fullStr | Association between daidzein intake and metabolic associated fatty liver disease: A cross-sectional study from NHANES 2017–2018 |
| title_full_unstemmed | Association between daidzein intake and metabolic associated fatty liver disease: A cross-sectional study from NHANES 2017–2018 |
| title_short | Association between daidzein intake and metabolic associated fatty liver disease: A cross-sectional study from NHANES 2017–2018 |
| title_sort | association between daidzein intake and metabolic associated fatty liver disease a cross sectional study from nhanes 2017 2018 |
| topic | daidzein MAFLD NHANES hepatic steatosis hepatic fibrosis |
| url | https://www.frontiersin.org/articles/10.3389/fnut.2023.1113789/full |
| work_keys_str_mv | AT zhengyang associationbetweendaidzeinintakeandmetabolicassociatedfattyliverdiseaseacrosssectionalstudyfromnhanes20172018 AT daoqinggong associationbetweendaidzeinintakeandmetabolicassociatedfattyliverdiseaseacrosssectionalstudyfromnhanes20172018 AT xinxianghe associationbetweendaidzeinintakeandmetabolicassociatedfattyliverdiseaseacrosssectionalstudyfromnhanes20172018 AT feihuang associationbetweendaidzeinintakeandmetabolicassociatedfattyliverdiseaseacrosssectionalstudyfromnhanes20172018 AT yisun associationbetweendaidzeinintakeandmetabolicassociatedfattyliverdiseaseacrosssectionalstudyfromnhanes20172018 AT qinminghu associationbetweendaidzeinintakeandmetabolicassociatedfattyliverdiseaseacrosssectionalstudyfromnhanes20172018 |